The Charnoly Body: A Novel Biomarker of Mitochondrial Bioenergetics

ISBN-13: 9781138557161 / Angielski / Twarda / 2019 / 388 str.

Sushil Sharma

Opis

This book highlights Charnoly body (CB) prevention/inhibition, charnolophagy induction, and charnolosome stabilization, as targets for safe and effective treatment of chronic intractable diseases (CIDs). Emerging glycomics, genomics, and epigenomics are described to further elucidate diversified charnolopathies.

Spis treści

GENERAL INTRODUCTION OF CHARNOLY BODY AS A NOVEL THERANOSTIC BIOMARKER (Basic Cellular and Molecular Biology). Free Radical–Induced Compromised Mitochondrial Bioenergetics Triggers Charnoly Body Formation. Free Radical-Induced Molecular Pathophysiology of Charnoly body and Charnolosome. Charnoly Body as a Novel Biomarker of Cell Injury. Charnoly Body as a Novel Biomarker of Compromised Mitochondrial bioenergetics. Antioxidants Prevent Charnoly Body Formation, Augment Charolophagy, and Stabilize Charnolosome to Enhance Mitochondrial bioenergetics and Intracellular Detoxification. Metallothioneins Inhibit Charnoly Body Formation and Confer Structural and Functional Stability to Charnolosome. Clinical Significance of Charnoly Body as a Biomarker of Compromized Mitochodrial Bioenergetics in Multidrug-Resistant Diseases. CHARNOLY BODY AS A BIOMARKERS IN DRUG DISCOVERY EMERGING BIOTECHNOLOGY IN CHARNOLY BODY RESEARCH (Personalized Theranostics). Development of Novel Charnolopharmacotherapeutics in Pharmaceutical Industry by Flow Cytometric Analysis. Charnoly Body as a Novel Biomarker in Nanomedicine. Clinical Significance of Mitochondrial Bioenergetic and Charnoly Body in Evidence Based Personalized Nanotheranostics. Translational Multimodality Neuroimaging of Charnoly Body, Charnolophagy, and Charnolosome for Personalized theranostics of Chronic MDR Diseases. PET Radiopharmaceuticals and Surface Plasmon Resonance Spectroscopy for Charnoly Body and micro-RNA Based Personalized Theranostics. Theranostic Potential of Stem Cells from Different Biological Sources as Charnoly Body Anagonists, Charnolophagy Agonists, and Charnolosome Stabilizers. Charnolopharmacotherapeutics of Chronic Multidrug Resistant Diseases by Metallothionein-Induced Hypoxia Inducible Factor-1. CHARNOLY BODY MOLECULAR PATHOGENESIS CLINICAL SIGNIFICANCE OF DISEASE-SPECIFIC CHARNOLY BODY FORMATION AND OTHER BIOMARKERS IN CHRONIC DISEASES (Recent Update on Evidence-Based Personalized Theranostics). Disease-Specific Charnoly Body Formation. Charnoly Body in Fetal Alcohol Syndrome. Charnoly Body in Nicotinism. Charnoly Body in ZIKV Disease. Charnoly Body in Malnutrition (Mitochondrial Bioenergetics in Health and Disease). Charnoly Body Formation in Drug Addiction and other Chronic Multi-Drug-Resistant Diseases (Therapeutic Potential of MTs). Charnoly Body in Cardiovascular Disease. Charnoly Body in Stroke. Charnoly Body in Traumatic Brain Injury and PTSD. Charnolopharmacotherapy of Neurodegenerative and other Diseases.

O autorze

Dr Sushil Sharma is a Professor and Course Director of Pharmacology at the Saint James School of Medicine in Saint Vincent & Grenadines. He received Ph.D. in Neuropharmacology from A.I.IM.S, New Delhi; Radiopharmaceutical Trainings from BARC, Bombay, GE, Siemens, Agilent Technologies, & Cardinal Health in the U.S. He has organized and chaired several world conferences, has been awarded 5 gold medals, a certificate of honor at I.T Nano-2014 Conference, Boston. (Original Discoveries: Electromicroinjector; Charnoly Body in Purkinje Neurons, IL-10 Receptors on Cortical Neurons, & MTs-Gene-Manipulated Mice), and authored 235 publications.